Contributions
Abstract: EP1173
Type: E-Poster Presentation
Session title: Quality of life, palliative care, ethics and health economics
Background
Highly effective drugs have significantly affected the outcomes of multiple myeloma, with a five-year survival improving from 34.6 % in 1998 to 53.9% in 2016. Since 2009 alone, more than a dozen new treatments have been approved by FDA continuing to improve quantity and quality of life in pts with MM. However, these drugs come at a huge financial cost and cost effectiveness analysis is commonly used tool to study economic impact of novel treatments.
Aims
Multiple drugs are being developed and approved for R/R Multiple Myeloma that has been treated with Immunomodulatory drugs, Proteasome Inhibitor and anti-CD38 monoclonal antibody (TCE). We aim to study economic evidence for FDA approved therapies in TCE Multiple Myeloma
Methods
Using survival probabilities by three response groups (partial or complete response; stable disease; and progressive disease) from clinical trials for Selinexor (STORM) and Belantamab mafodotin (DREAMM-2), we estimated incremental cost effectiveness ratios from a healthcare sector perspective comparing the two treatments. We modeled 12-month treatment and severe adverse effects costs, life-years gained, and an incremental cost-effectiveness ratio among a hypothetical cohort of adults age 40 to 80 using a Markov model.
Results
The expected value of the 12-month treatment costs per life gained were $251,211 and $239,749 for Selinexor and Belantamab, respectively. Extrapolating response rates for the hypothetical cohort over a longer period suggested Selinexor treatment costs $96,170 per discounted quality-adjusted life-year (QALY) and Belantamab costs $89,521 per discounted QALY.
Conclusion
Outcomes for patients with TCE Myeloma is poor with limited therapeutic options and carry a significant cost burden. With scientific advances, we are at verge of paradigm shift with anticipated regulatory approval of therapeutic options agents like novel alkylating agents, newer immunomodulatory drugs, CAR T-cell and Bispecific Antibodies. Our study is the first to provide critically required economical perspective in choosing appropriate agents in TCE Multiple Myeloma.
Keyword(s): Cost analysis, Cost effectiveness, Myeloma
Abstract: EP1173
Type: E-Poster Presentation
Session title: Quality of life, palliative care, ethics and health economics
Background
Highly effective drugs have significantly affected the outcomes of multiple myeloma, with a five-year survival improving from 34.6 % in 1998 to 53.9% in 2016. Since 2009 alone, more than a dozen new treatments have been approved by FDA continuing to improve quantity and quality of life in pts with MM. However, these drugs come at a huge financial cost and cost effectiveness analysis is commonly used tool to study economic impact of novel treatments.
Aims
Multiple drugs are being developed and approved for R/R Multiple Myeloma that has been treated with Immunomodulatory drugs, Proteasome Inhibitor and anti-CD38 monoclonal antibody (TCE). We aim to study economic evidence for FDA approved therapies in TCE Multiple Myeloma
Methods
Using survival probabilities by three response groups (partial or complete response; stable disease; and progressive disease) from clinical trials for Selinexor (STORM) and Belantamab mafodotin (DREAMM-2), we estimated incremental cost effectiveness ratios from a healthcare sector perspective comparing the two treatments. We modeled 12-month treatment and severe adverse effects costs, life-years gained, and an incremental cost-effectiveness ratio among a hypothetical cohort of adults age 40 to 80 using a Markov model.
Results
The expected value of the 12-month treatment costs per life gained were $251,211 and $239,749 for Selinexor and Belantamab, respectively. Extrapolating response rates for the hypothetical cohort over a longer period suggested Selinexor treatment costs $96,170 per discounted quality-adjusted life-year (QALY) and Belantamab costs $89,521 per discounted QALY.
Conclusion
Outcomes for patients with TCE Myeloma is poor with limited therapeutic options and carry a significant cost burden. With scientific advances, we are at verge of paradigm shift with anticipated regulatory approval of therapeutic options agents like novel alkylating agents, newer immunomodulatory drugs, CAR T-cell and Bispecific Antibodies. Our study is the first to provide critically required economical perspective in choosing appropriate agents in TCE Multiple Myeloma.
Keyword(s): Cost analysis, Cost effectiveness, Myeloma